BridgeBio Q3: Revenue Triples to $353M, Loss Narrows to $60M, Cash Reaches $1.5B
BBIO sits 17% above its 52-week low of $60.22 on elevated volume (2.0× avg).
Summary
BridgeBio's Q3 revenue tripled to $353.2M and the operating loss shrank to $11.6M, with $1.54B of cash after a $933.9M preferred raise. The 2027 and 2031 convertible notes are now in their conversion windows, putting roughly $1.1B of principal in play against a $70.69 stock.
Key Events · Earnings and Guidance · BBIO
-
Q3 Revenue Triples on Attruby
Total revenue of $353.2M versus $120.7M a year ago, including $253.3M of net product revenue and a $75.0M Bayer sales milestone; operating loss narrowed to $11.6M from $145.2M.
-
Cash Jumps to $1.54B
Cash, cash equivalents and marketable securities reached $1.54B at September 30, 2026 from $587.5M at year-end, after $932.6M net preferred proceeds and $632.5M of 2033 notes; nine-month operating cash burn was $312.6M.
-
Convertible Notes Enter Conversion Window
The $550M 2027 notes (conversion price $42.71) and $575M 2031 notes ($49.81) are convertible from October 1, 2026 through December 14 and December 31 respectively, after the stock-price condition was met; the 2027 notes moved to current liabilities.
-
Preferred Dividend Costs $26.3M
The 933,900 Series A preferred shares ($933.9M raised at $1,000 each, convertible at $137.79 into 6,777,704 common shares) carry a 7.00% cash dividend that cost $26.3M including $9.9M of accretion in Q3.
Analysis · BBIO · Life Sciences
The Attruby launch is compounding: revenue reached $353.2M against $120.7M a year ago, and the operating loss shrank to $11.6M from $145.2M. The balance sheet changed even more — $1.54B of cash and securities after the $933.9M preferred raise and $632.5M of 2033 notes, set against $2.5B of convertible debt and $920.1M of deferred royalty obligations. Two items matter for holders now. First, the 2027 notes ($550M, 2.50%) and 2031 notes ($575M, 1.75%) both became convertible from October 1, 2026 because the stock traded above the trigger; holders can elect conversion into a stock trading at $70.69 versus conversion prices of $42.71 and $49.81, so this is real potential share issuance, not a paper entry. Second, the preferred carries a 7% cash dividend that cost $26.3M in Q3 alone and steps up over time — a permanent claim ahead of common. Management says current cash funds at least 12 months of operations.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $70.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $60.22 to $93.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.